tulrampator

Tulrampator (also known as S-47445 or CX-1632) is a small molecule positive allosteric modulator (PAM) of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor. Developed by Servier under license from Resverlogix, it belongs to the 'Ampakine' class of compounds. Tulrampator works by binding to an allosteric site on the AMPA receptor, which slows the rate of receptor desensitization and deactivation in the presence of the endogenous neurotransmitter glutamate. This action prolongs the opening of the ion channel, thereby enhancing excitatory postsynaptic currents and promoting synaptic plasticity. Additionally, tulrampator has been shown to increase the expression of brain-derived neurotrophic factor (BDNF), a protein critical for neuronal survival and growth. The drug has been primarily investigated in Phase 2 clinical trials for the treatment of major depressive disorder (MDD) and cognitive impairment associated with Alzheimer's disease, aiming to address the glutamatergic dysfunction often observed in these conditions.

Other names

tulrampator